TRANSRADIAL ARTERY ACCESS DEVICES

{0}------------------------------------------------ K112554 P. 1 of 2 | 5. 510(k) Summary | NOV 18 2011 | |--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Submitter: | ARROW International, Inc.<br>2400 Bernville Road<br>Reading, PA 19605-9607 USA | | Contact person: | Christine Ford, Sr. Regulatory Affairs Specialist<br>Phone: 610-378-0131, ext. 3338<br>Fax: 610-478-3179<br>Email: christine.ford@teleflex.com | | Date summary prepared: | August 31, 2011 | | Device trade name: | TransRadial Artery Access Device | | Device common name: | Percutaneous sheath introducer | | Device classification<br>name: | Class II, DYB, Introducer, Catheter, 21 CFR 870.1340 | | Legally marketed device<br>to which the device is<br>substantially equivalent: | Arrow Percutaneous Sheath Introducers, K780532<br>Terumo Glidesheath™ Catheter Introducer Sheath, K082644 | | Description of the device: | The TransRadial Artery Access devices are comprised of the<br>components required to perform percutaneous transradial artery<br>access: an introducer needle, a guide wire, a dilator, and a<br>percutaneous sheath introducer with hemostasis valve and sidearm<br>assembly with a stopcock. | | Intended use of the<br>device: | The TransRadial Artery Access Device is intended for use for<br>percutaneous introduction of devices into the radial artery for<br>diagnostic and therapeutic purposes. | | Technological<br>characteristics: | The TransRadial Artery Access devices use the same fundamental<br>technology as the aforementioned predicate percutaneous catheter<br>introducer devices. All provide the device components necessary<br>for introduction of a catheter into a vessel using the Seldinger<br>technique. | | Performance tests: | To demonstrate safety and functional efficacy of the TransRadial<br>Artery Access devices, the following tests were performed on the<br>device components and met acceptability requirements:<br>• Biocompatibility in accordance with ISO 10993-1: cytotoxicity,<br>sensitization, intracutaneous reactivity, systemic toxicity,<br>hemocompatibility, and rabbit pyrogen<br>• Introducer needle testing: surface, bevel, and needle point visual<br>inspections, corrosion resistance, radiodetectability, hub to | {1}------------------------------------------------ cannula and guidewire interface, hub female luer lock testing (air and liguid leakage, separation force, unscrewing torque, ease of assembly, resistance to overriding, and stress cracking), strength of union of needle tube and needle hub, penetration force, and needle bevel alignment and dimensional analysis - introducer testing: surface visual inspection. · Sheath radiodetectability, freedom from leakage from sheath introducer, freedom from leakage through hemostasis valve, sidearm stopcock hub luer lock testing (air and liquid leakage, separation force, unscrewing torque, ease of assembly, resistance to overriding, and stress cracking), force at break between sheath introducer and the junction between sheath introducer and the hub (hemostasis valve), and force at break between hemostasis valve body barb to side arm extrusion and side arm extrusion to stopcock - · Guide wire testing: surface visual inspection, lateral stiffness, corrosion resistance, radiodetectability, fracture, flexing, strength of union of core wire and coil, and tensile strength pull testing - · Dilator testing: surface visual inspection, radiodetectability, dilator hub luer slip testing (air and liquid leakage, separation force, stress cracking), and strength of union between hub and dilator - · Sheath/dilator assembly testing: sheath/dilator rollback upon insertion, sheath/dilator insertion force, sheath/dilator assembly rigidity, and sheath and dilator dimensional inspections - · Overall device component compatibility testing The described intended use, results of verification testing performed. and comparison testing to the predicate devices demonstrated that the subject devices are substantially equivalent to the legally marketed predicate intravascular catheter introducer devices, the Arrow Percutaneous Sheath Introducers and Terumo Glidesheath™ Catheter Introducer Sheath. Any differences between the proposed and predicate devices do not raise new issues of safety and effectiveness. # Conclusions: {2}------------------------------------------------ # DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/2/Picture/1 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features an abstract image of an eagle with its wings spread, symbolizing protection and care. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle, indicating the department's name and national affiliation. The seal is rendered in black and white, giving it a formal and official appearance. #### Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 NOV 1 8 2011 Arrow International, Inc. Subsidiary of Teleflex Medical Inc. c/o Christine Ford Senior Regulatory Affairs Specialist 2400 Bernville Road Reading, PA 19605 . Re: K112554 Trade/Device Name: Arrow TransRadial Artery Access Device Regulation Number: 21 CFR 870.1340 Regulation Name: Catheter Introducer Regulatory Class: Class II Product Code: DYB Dated: August 30, 2011 Received: September 2, 2011 ### Dear Ms. Ford: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. However, we remind you that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {3}------------------------------------------------ Page 2 - Ms. Christine Ford Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited.to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely oppurs. , Bram Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ #### 4. INDICATIONS FOR USE STATEMENT 510(k) Number (if known) K112554 Device Name TransRadial Artery Access Devices Indications for Use The TransRadial Artery Access Device is intended for use for percutaneous introduction of devices into the radial artery for diagnostic and therapeutic purposes. Prescription Use X (Per 21 CFR 801. 109) OR Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ ## PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) ular Devices Division of Cardiov 510(k) Number